China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China SXT Pharmaceuticals Inc
Cash from Financing Activities
China SXT Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
Cash from Financing Activities
$6.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Financing Activities
-¥1.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Financing Activities
¥7.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Financing Activities
-¥4.3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-22%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash from Financing Activities
-¥4.5B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Financing Activities
¥1.3B
|
CAGR 3-Years
143%
|
CAGR 5-Years
144%
|
CAGR 10-Years
N/A
|
|
China SXT Pharmaceuticals Inc
Glance View
China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 96 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
See Also
What is China SXT Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
6.5m
USD
Based on the financial report for Sep 30, 2025, China SXT Pharmaceuticals Inc's Cash from Financing Activities amounts to 6.5m USD.
What is China SXT Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
-28%
Over the last year, the Cash from Financing Activities growth was -28%.
